Repligen (NASDAQ:RGEN) Stock Price Up 5.9% - Here's Why

Key Points

• Repligen shares rose 5.9% to $186.80, supported by favorable analyst sentiment. The stock has a consensus “Buy” rating, with an average price target of $166.43.
• The company’s latest quarterly results exceeded expectations, with EPS of $0.54 versus the $0.45 consensus and revenue of $204.13 million. Revenue increased 11.9% year over year, and management issued fiscal-year EPS guidance of $2.03–$2.09.
• Institutional investors own a substantial 97.64% of Repligen’s shares, while recent filings showed several funds increasing their positions; the CFO separately sold 733 shares.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) shares were up 5.9% during trading on Thursday . The stock traded as high as $186.80 and last traded at $186.80. Approximately 645,660 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 1,015,015 shares. The stock had previously closed at $176.36.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. Royal Bank Of Canada started coverage on Repligen in a report on Thursday, May 14th. They set an "outperform" rating and a $160.00 price objective for the company. JPMorgan Chase & Co. upped their price target on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Repligen presently has a consensus rating of "Buy" and an average price target of $166.43.

Repligen Stock Performance

The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock's 50 day moving average price is $145.21 and its 200 day moving average price is $131.32. The company has a market capitalization of $10.39 billion, a price-to-earnings ratio of 252.26, a P/E/G ratio of 3.03 and a beta of 1.03.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.Repligen's revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts expect that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company's stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in Repligen during the first quarter worth $262,000. Jones Financial Companies Lllp increased its position in Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after acquiring an additional 6,238 shares during the period. Goldman Sachs Group Inc. increased its position in Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after acquiring an additional 20,375 shares during the period. Bank of Nova Scotia raised its stake in Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company's stock worth $3,951,000 after purchasing an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company's stock valued at $3,880,000 after purchasing an additional 7,148 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source